Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott T Tagawa

Showing results (161-170 of 208) with videos related to

Pageof 21
Sort By:
Nature Communications|December 4, 2020
Common germline-somatic variant interactions in advanced urothelial cancerAram Vosoughi, Tuo Zhang, Kyrillus S Shohdy, et al.
European Urology|June 26, 2012
Pathologic nodal staging score for bladder cancer: a decision tool for adjuvant therapy after radical cystectomyShahrokh F Shariat, Michael Rink, Behfar Ehdaie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2024
Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway)Maha Hussain, Masha Kocherginsky, Neeraj Agarwal, et al.
Cancer|December 22, 2017
Bone biopsy protocol for advanced prostate cancer in the era of precision medicineVerena Sailer, Marc H Schiffman, Myriam Kossai, et al.
Radiology|August 20, 2024
Quantitative <sup>68</sup>Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following <sup>177</sup>Lu-PSMA-617 (VISION Trial)Phillip H Kuo, Michael J Morris, Jacob Hesterman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2016
Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II TrialDaniel P Petrylak, Scott T Tagawa, Manish Kohli, et al.
European Urology|August 11, 2012
Extranodal extension is a powerful prognostic factor in bladder cancer patients with lymph node metastasisHarun Fajkovic, Eugene K Cha, Claudio Jeldres, et al.
BJU International|July 20, 2012
Outcomes and prognostic factors in patients with a single lymph node metastasis at time of radical cystectomyMichael Rink, Jens Hansen, Eugene K Cha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2018
A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and BiomarkersHimisha Beltran, Clara Oromendia, Daniel C Danila, et al.
Cancer Discovery|March 6, 2012
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targetsHimisha Beltran, David S Rickman, Kyung Park, et al.
Pageof 21

Showing results (161-170 of 208) with videos related to

Sort By:
Pageof 21
Nature Communications|December 4, 2020
Common germline-somatic variant interactions in advanced urothelial cancerAram Vosoughi, Tuo Zhang, Kyrillus S Shohdy, et al.
European Urology|June 26, 2012
Pathologic nodal staging score for bladder cancer: a decision tool for adjuvant therapy after radical cystectomyShahrokh F Shariat, Michael Rink, Behfar Ehdaie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2024
Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway)Maha Hussain, Masha Kocherginsky, Neeraj Agarwal, et al.
Cancer|December 22, 2017
Bone biopsy protocol for advanced prostate cancer in the era of precision medicineVerena Sailer, Marc H Schiffman, Myriam Kossai, et al.
Radiology|August 20, 2024
Quantitative <sup>68</sup>Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following <sup>177</sup>Lu-PSMA-617 (VISION Trial)Phillip H Kuo, Michael J Morris, Jacob Hesterman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2016
Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II TrialDaniel P Petrylak, Scott T Tagawa, Manish Kohli, et al.
European Urology|August 11, 2012
Extranodal extension is a powerful prognostic factor in bladder cancer patients with lymph node metastasisHarun Fajkovic, Eugene K Cha, Claudio Jeldres, et al.
BJU International|July 20, 2012
Outcomes and prognostic factors in patients with a single lymph node metastasis at time of radical cystectomyMichael Rink, Jens Hansen, Eugene K Cha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2018
A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and BiomarkersHimisha Beltran, Clara Oromendia, Daniel C Danila, et al.
Cancer Discovery|March 6, 2012
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targetsHimisha Beltran, David S Rickman, Kyung Park, et al.
Pageof 21